Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC
Nat Med. 2009 15 (4): 380-3

PMID: 19330009 · PMCID: PMC2904954 · DOI:10.1038/nm.1942

Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal inherited arrhythmia syndrome in which drug therapy is often ineffective. We discovered that flecainide prevents arrhythmias in a mouse model of CPVT by inhibiting cardiac ryanodine receptor-mediated Ca(2+) release and thereby directly targeting the underlying molecular defect. Flecainide completely prevented CPVT in two human subjects who had remained highly symptomatic on conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy for CPVT.

MeSH Terms (14)

Animals Anti-Arrhythmia Agents Arrhythmias, Cardiac Calcium Child Flecainide Heart Rate Humans Male Mice Polymorphism, Genetic Ryanodine Receptor Calcium Release Channel Syndrome Tachycardia, Ventricular

Connections (3)

This publication is referenced by other Labnodes entities: